Bell2Bell Podcast featuring CEO Rodney Varner & CFO Ryan Confer of Genprex, Inc. (NASDAQ: GNPX) [Video Edition]
Bell2Bell’s latest podcast features Chairman, President and CEO Rodney Varner and CFO Ryan Confer of Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes.
In this interview, Varner and Confer discuss the journeys that led them to Genprex and the incredible promise of the company’s clinical drug development pipeline.
“This work has become a real passion for me. We have the opportunity to do real good here at Genprex on a major scale – helping millions of people around the world with serious diseases through our novel gene therapies,” said Varner.
Confer then provided some background on what led him to join Genprex in its early days and remain with the company for well over a decade.
“As I learned more and more about the technology, it became a passion of mine, as well,” said Confer. “What we’re trying to do in cancer – using a lipid-based delivery vehicle and working with tumor suppressor genes that are naturally occurring in the body – represents a treatment paradigm that is unique and different than other options in the space, particularly chemotherapy that has such negative side effects. It is something that we believe really has the potential to change people’s lives as they’re going through such a terrible prognosis. I was excited then, and here we are 12 years later, being able to see it coming through clinical trials, seeing how safe the program has been and seeing the impact that we’re having.”
It is Free